Inflammatory Bowel Disease

• On the basis of level A research, the pathogenesis of inflammatory bowel disease (IBD) is attributed to a combination of genetic and environmental factors. (1) • On the basis of level A research, various putative environmental exposures attributed to increased IBD susceptibility result in alterations in the microbiome, which is referred to as dysbiosis. (2) • On the basis of level A research, the worldwide incidence and prevalence of IBD is increasing. (3) • On the basis of level A research, biologic agents such as infliximab and adalimumab are effective therapies for pediatric patients with moderate-to-severe disease. (4)(5)(6) • On the basis of level A research, a multidisciplinary team approach that takes into account numerous biopsychosocial variables and that addresses issues related to medication adherence is important for successful management of IBD. (7). Copyright © 2016 by the American Academy of Pediatrics. All rights reserved.